drugset / Trial / NCT04083963
Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
Nonrandomized, open label, single arm, Simon's two stage MinMax design trial of neoadjuvant weekly carboplatin plus paclitaxel, followed by doxorubicin and cyclophosphamide in patients with operable Triple Negative Breast Cancer (TNBC)
Timeline
- Start
- 2019-08-09
- Primary completion
- 2026-09-27
- Completion
- 2026-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 2 unknown | Other |
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 60 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Other |